China SXT Pharmaceuticals (SXTC) Short term Debt (2018 - 2026)
China SXT Pharmaceuticals (SXTC) posted quarterly Short term Debt of $355175.0 for Q1 2026, up 3944.81% year-on-year from $8781.0 in Q1 2025, and up 7836.87% on a QoQ basis from $4475.0 in Q3 2025.
China SXT Pharmaceuticals (SXTC) Short term Debt (2018 - 2026) Analysis & Trends
China SXT Pharmaceuticals (SXTC) has reported Short term Debt for 9 consecutive years, with $355175.0 the latest figure, recorded in Q1 2026.
- Quarterly Short term Debt rose 3944.81% year-over-year to $355175.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $355175.0 (up 3944.81% YoY) and the FY2026 annual result came in at $355175.0, up 3944.81% from the prior year.
- Short term Debt rose to $355175.0 in Q1 2026 per SXTC's latest filing, from $4475.0 in the prior quarter.
- Over the last five years, Short term Debt for SXTC reached as high as $1.2 million in Q3 2022 and fell as low as $4475.0 in Q3 2025.
- A 5-year average of $328272.8 and a median of $167453.0 in 2023 frame the typical range for Short term Debt.
- Annual changes were most pronounced in 2022 — Short term Debt sank 99.91% — and 2024, when it soared 11960.87%.
- Year by year, Short term Debt stood at $1.2 million in 2022, then slumped by 99.52% to $5822.0 in 2023, then surged by 11960.87% to $702184.0 in 2024, then plunged by 99.36% to $4475.0 in 2025, then surged by 7836.87% to $355175.0 in 2026.
- According to Business Quant data, Short term Debt over the past three periods registered $355175.0, $4475.0, and $8781.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | China SXT Pharmaceuticals | 7.11 Mn | -21.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 355,175.00 |
| Sep 30, 2025 | 4,475.00 |
| Mar 31, 2025 | 8,781.00 |
| Sep 30, 2024 | 702,184.00 |
| Mar 31, 2024 | 493,054.00 |
| Sep 30, 2023 | 5,822.00 |
| Mar 31, 2023 | 167,453.00 |
| Sep 30, 2022 | 1.21 Mn |
| Mar 31, 2022 | 11,404.00 |
| Sep 30, 2021 | 2.12 Mn |
| Mar 31, 2021 | 12.15 Mn |
| Sep 30, 2020 | 45,757.00 |
| Mar 31, 2020 | 6.64 Mn |
| Sep 30, 2019 | 1.83 Mn |
| Mar 31, 2019 | 2.48 Mn |
| Sep 30, 2018 | 205,452.00 |